Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy

Clin Exp Dermatol. 2018 Mar;43(2):234-236. doi: 10.1111/ced.13302. Epub 2017 Dec 28.

Authors

B H L Harris^{1

2}, J L Walsh³, R Neciunaite⁴, P Manders¹, A Cooper^{1

5

6}, P De Souza^{1

5

6}

Affiliations

¹ Department of Medical Oncology, Liverpool Hospital, Sydney, Australia.
² St. Anne's College, Oxford University, Oxford, UK.
³ St. George's Hospital, London, UK.
⁴ Cardiff University School of Medicine, Cardiff, UK.
⁵ Western Sydney University School of Medicine, Sydney, Australia.
⁶ Ingham Institute, Liverpool, Sydney, Australia.

PMID: 29282751
DOI: 10.1111/ced.13302

No abstract available

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Humans
Indazoles
Male
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / therapeutic use*
Sarcoma, Kaposi / drug therapy*
Sulfonamides / therapeutic use*
Treatment Outcome

Substances

Indazoles
Protein Kinase Inhibitors
Pyrimidines
Sulfonamides
pazopanib
Protein-Tyrosine Kinases